Episode Summary
Executive Summary: Tim Ferriss interviews Tanya DeJong about how she and her husband helped make Australia the first country to allow MDMA and psilocybin prescriptions for psychiatric conditions. The conversation traces their personal psychedelic experiences, coalition-building strategy, regulator lobbying, clinician training, payer engagement, and the importance of persistence, data, and public storytelling in driving major policy change.
Main Topics: Personal psychedelic experiences as catalyst (Priority: 5/5): DeJong describes how first psilocybin sessions profoundly changed her worldview, reduced control tendencies, deepened her relationship with her husband, and inspired her to pursue broader access. Building Mind Medicine Australia (Priority: 5/5): The couple launched Mind Medicine Australia in 2019 after realizing the potential of psychedelic-assisted therapy and seeing limited Australian research and access at the time. Regulatory strategy and rescheduling campaign (Priority: 5/5): A major theme is the multi-year effort to move MDMA and psilocybin from prohibited status into a prescribable medical category through repeated submissions, public consultation, and direct engagement with the TGA. Coalition-building and public persuasion (Priority: 5/5): DeJong explains how they recruited researchers, clinicians, philanthropists, lobbyists, and public advocates, and used webinars, town halls, roadshows, and emotional patient stories to build momentum. Training clinicians and creating infrastructure (Priority: 4/5): Mind Medicine Australia developed a certificate program in psychedelic-assisted therapy, trained hundreds of clinicians, and helped establish clinics and protocols for safe delivery. Access, cost, and payer adoption (Priority: 4/5): The discussion covers the high upfront cost of treatment, the need for patient support funding, and the successful outreach to payers such as veterans' services, disability insurance, and private insurers. Integration, outcomes, and future expansion (Priority: 4/5): They discuss integration therapy, real-world evidence collection, remission rates, and the future of group-based and expanded-access models in Australia and beyond.
Key Arguments: A determined outsider with no formal psychedelic background can still drive major policy change if they build credibility, recruit experts, and persist through setbacks. Public storytelling and emotionally compelling patient cases can be as important as scientific data in shifting regulators and stakeholders. Regulatory change was achieved through iterative submissions that directly addressed objections raised by the TGA, not through a single breakthrough meeting. Training clinicians and creating a treatment ecosystem was essential; policy change alone would not have produced patient access without practitioners and clinics. Real-world evidence collection is critical because it helps demonstrate safety, remission rates, and cost savings to governments and payers. Access should remain controlled and clinically supervised, but overly restrictive rules can become barriers to treatment for severely ill patients. Patient support funds and payer participation are necessary because the main cost driver is therapy time, not the medicines themselves. The medicines are not magic bullets; outcomes depend on preparation, the session itself, and integration with lifestyle and behavioral change afterward.
Data Points: Country first: Australia became the first country in the world to allow MDMA and psilocybin to be prescribed for psychiatric conditions - DeJong describes the 2023 TGA rescheduling as a global first Launch date: February 2019 - Mind Medicine Australia was launched Initial rescheduling attempt: Late 2020 - First approach to the Therapeutic Goods Administration Public submissions: 13,000+ Australians - Support for the final rescheduling submission Public support rate: 98%+ - Share of submissions supporting rescheduling Clinicians trained: 750+ - Mind Medicine Australia’s psychedelic-assisted therapy certificate program Clinics in Australia: 20+ - Clinics now prescribing or delivering treatment Patients treated: 400+ - Approximate number treated in Australia Authorized prescribers: 120 - Current number of authorized prescribing psychiatrists in Australia Patient support goal: A$2.5 million - Target amount to expand access via the patient support fund Treatment cost: A$8,000 to A$25,000 - Approximate cost range depending on number of doses and integration 70/30 split: ~70% MDMA / 30% psilocybin - Approximate treatment mix at the time discussed Remission rate: 60% to 80% - Reported outcomes in Australian clinical use and trials Existing-treatment remission: 10% to 15% - Comparison baseline mentioned for PTSD/depression treatments Therapy training timeline: Started in 2021 - Beginning of clinician training program Social scale: 30+ chapters - Community chapters across Australia
Pivotal Quotes: "This is the biggest amount of public submissions ever received by our regulators for rescheduling any medicines." — Tanya DeJong: Describing the scale of public pressure on the TGA "We just thought, well, anything's possible. We can do this." — Tanya DeJong: Summarizing the campaign mindset and persistence "We're all walking each other home." — Ram Dass (quoted by Tanya DeJong): Used to frame the relational and spiritual ethos behind their work
Implications: The episode shows that major drug-policy reform can come from persistent coalition-building, public education, and clinician infrastructure. For advocates, the blueprint is clear: build evidence, build allies, and keep going.
About The Tim Ferriss Show
Tim Ferriss is a self-experimenter and bestselling author, best known for The 4-Hour Workweek. In this show, he deconstructs world-class performers from eclectic areas (investing, sports, business, art, etc.) to extract the tactics, tools, and routines you can use.